



October 19, 2010

Re: **IMPORTANT PRODUCT SUPPLY INFORMATION**

**Antivenin (Micrurus fulvius) (Equine Origin)
North American Coral Snake Antivenin**

**FURTHER EXTENSION OF EXPIRATION DATING TO OCTOBER 31, 2011
LOT NO. 4030026**

Dear Health Care Provider:

Wyeth Pharmaceuticals (a subsidiary of Pfizer, Inc) would like to provide you with updated and very important information regarding Antivenin (Micrurus fulvius) (Equine Origin) North American Coral Snake Antivenin.

Last October, Wyeth Pharmaceuticals announced the extension of the expiration date of one lot of Antivenin, Lot No. 4030026, until October 31, 2010, an additional 24 months beyond the labeled expiration date of October 31, 2008.

Wyeth Pharmaceuticals, working closely with the U.S. Food and Drug Administration (FDA), is further extending the expiration date of Lot No. 4030026 for an additional 12 months. Wyeth Pharmaceuticals has stability data that indicate product from Lot No. 4030026 continues to be within applicable release specifications. **As a result, product from this lot will now be deemed to expire on October 31, 2011.**

As you may know, Wyeth Pharmaceuticals no longer manufactures Antivenin, and there is currently no alternative FDA-approved supplier of this product. **Accordingly, it is imperative that you do not discard any product you have in your inventory of Lot No. 4030026. Please continue to maintain this product in your inventory and keep it available for use until October 31, 2011.**

Wyeth is carefully managing Antivenin (Micrurus fulvius) inventories and will supply product only to direct customers.

Antivenin (Micrurus fulvius) (Equine Origin) is indicated for the treatment of envenomation caused by the bites of M. f. fulvius (eastern coral snake) and M. f. teneris (Texas coral snake). Please see accompanying full Prescribing Information for indications and usage, dosage and administration, and important safety information. Also, the product Prescribing Information can be accessed at www.wyeth.com.

If you have any questions, please call our Customer Service Department at 1-800-666-7248.

Sincerely,

A handwritten signature in black ink, appearing to read 'RU' followed by a long horizontal flourish.

Raymond W. Urbanski, MD, PhD
Vice President, Clinical Development
and Medical Affairs
Established Products Business Unit
Pfizer, Inc.
cc: US FDA